» Articles » PMID: 24465503

Mobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-effectiveness

Abstract

Background: Mobile HIV screening may facilitate early HIV diagnosis. Our objective was to examine the cost-effectiveness of adding a mobile screening unit to current medical facility-based HIV testing in Cape Town, South Africa.

Methods And Findings: We used the Cost Effectiveness of Preventing AIDS Complications International (CEPAC-I) computer simulation model to evaluate two HIV screening strategies in Cape Town: 1) medical facility-based testing (the current standard of care) and 2) addition of a mobile HIV-testing unit intervention in the same community. Baseline input parameters were derived from a Cape Town-based mobile unit that tested 18,870 individuals over 2 years: prevalence of previously undiagnosed HIV (6.6%), mean CD4 count at diagnosis (males 423/µL, females 516/µL), CD4 count-dependent linkage to care rates (males 31%-58%, females 49%-58%), mobile unit intervention cost (includes acquisition, operation and HIV test costs, $29.30 per negative result and $31.30 per positive result). We conducted extensive sensitivity analyses to evaluate input uncertainty. Model outcomes included site of HIV diagnosis, life expectancy, medical costs, and the incremental cost-effectiveness ratio (ICER) of the intervention compared to medical facility-based testing. We considered the intervention to be "very cost-effective" when the ICER was less than South Africa's annual per capita Gross Domestic Product (GDP) ($8,200 in 2012). We projected that, with medical facility-based testing, the discounted (undiscounted) HIV-infected population life expectancy was 132.2 (197.7) months; this increased to 140.7 (211.7) months with the addition of the mobile unit. The ICER for the mobile unit was $2,400/year of life saved (YLS). Results were most sensitive to the previously undiagnosed HIV prevalence, linkage to care rates, and frequency of HIV testing at medical facilities.

Conclusion: The addition of mobile HIV screening to current testing programs can improve survival and be very cost-effective in South Africa and other resource-limited settings, and should be a priority.

Citing Articles

Protocol for the economic evaluation of integrated community-based care compared with integrated facility-based care for HIV, hypertension and diabetes in Tanzania and Uganda (INTE-COMM trial).

Abou Jaoude G, Namakoola I, Aikaeli F, Kimaro G, Moyo F, Kasujja F NIHR Open Res. 2025; 4:80.

PMID: 40027170 PMC: 11868744. DOI: 10.3310/nihropenres.13794.2.


The impact of tobacco smoking and smoking cessation on lung cancer and stroke incidence among people with HIV on antiretroviral therapy in South Africa: a simulation modeling study.

DCouto H, Thielking A, Sewpaul R, Levy D, Rigotti N, Chrysanthopoulou S BMJ Glob Health. 2024; 9(12).

PMID: 39675836 PMC: 11647297. DOI: 10.1136/bmjgh-2024-017049.


Relationship between universal health insurance benefits and prostate cancer mortality in Colombia.

Mejia E, Lewis A, Garces-Palacio I, Hernandez D, Chamberlain R, Soliman A BMC Public Health. 2024; 24(1):2667.

PMID: 39350101 PMC: 11441010. DOI: 10.1186/s12889-024-20117-4.


Costs of HIV testing services in sub-Saharan Africa: a systematic literature review.

Ahmed N, Ong J, McGee K, dElbee M, Johnson C, Cambiano V BMC Infect Dis. 2024; 22(Suppl 1):980.

PMID: 39192180 PMC: 11348535. DOI: 10.1186/s12879-024-09770-7.


Tobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling study.

Thielking A, Fitzmaurice K, Sewpaul R, Chrysanthopoulou S, Dike L, Levy D J Int AIDS Soc. 2024; 27(6):e26315.

PMID: 38924347 PMC: 11197963. DOI: 10.1002/jia2.26315.


References
1.
Ivers L, Kendrick D, Doucette K . Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis. 2005; 41(2):217-24. DOI: 10.1086/431199. View

2.
Holmes C, Wood R, Badri M, Zilber S, Wang B, Maartens G . CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006; 42(4):464-9. DOI: 10.1097/01.qai.0000225729.79610.b7. View

3.
Venkatesh K, Lurie M, Mayer K . How HIV treatment could result in effective prevention. Future Virol. 2010; 5(4):405-415. PMC: 2929800. DOI: 10.2217/fvl.10.38. View

4.
Bassett I, Giddy J, Nkera J, Wang B, Losina E, Lu Z . Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr. 2007; 46(2):181-6. PMC: 2140230. DOI: 10.1097/QAI.0b013e31814277c8. View

5.
Brinkhof M, Pujades-Rodriguez M, Egger M . Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One. 2009; 4(6):e5790. PMC: 2686174. DOI: 10.1371/journal.pone.0005790. View